AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01498835
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual.
Trial: NCT00467610
Drug: Panhematin
RxNorm normalized name: Panhematin
DrugBank: Hemin (DB03404)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00070655
Drug: SR34006 (idraparinux sodium) Injection
RxNorm normalized name: Idraparinux
DrugBank: Idraparinux (DB06406)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01641510
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
Trial: NCT01641510
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
Trial: NCT01724359
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
Trial: NCT03676023
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhalation of Transexamic acid in age adjusted dosing
Trial: NCT02570841
Drug: Topical High dose Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
Trial: NCT00389727
Drug: Radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy
Trial: NCT03927807
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity.
Trial: NCT01263704
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg/m\^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
Trial: NCT01263704
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 IV Day 0 of Cycle 1, 500 mg/m\^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
Trial: NCT00458068
Drug: Oral administration of ferrous sulphate
RxNorm normalized name: ferrous fumarate Oral Capsule
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02341105
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antiarrhythmic therapy using Amiodarone
Trial: NCT00390598
Drug: PEG (solution given 4 L)
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00390598
Drug: senna glycoside 36 mg and PEG (solution given 2 L)
RxNorm normalized name: senna glycosides
DrugBank: Sennosides (DB11365)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02499978
Drug: Darunavir/Cobicistat
RxNorm normalized name: darunavir/cobicistat 800 mg-150 mg ORAL TABLET
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fixed dose combination medication
Trial: NCT02499978
Drug: Dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single tablet medication
Trial: NCT05400915
Drug: Variltinib, Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest period of 1 week.
Trial: NCT00945997
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
Trial: NCT00945997
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
Trial: NCT01149811
Drug: Fipamezole ODT
RxNorm normalized name: Fipamezole
DrugBank: Fipamezole (DB06585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
Trial: NCT01149811
Drug: Fipamezole ODT Cohort 2
RxNorm normalized name: Fipamezole
DrugBank: Fipamezole (DB06585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
Trial: NCT01502280
Drug: 5-Aminolevulinic acid (ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Following informed consent, within 3 hours prior to surgery, patient will orally ingest \[or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)\] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
Trial: NCT00545233
Drug: peginterferon alfa-2a [Pegasys]
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 micrograms subcutaneous weekly for 48 weeks
Trial: NCT00545233
Drug: ribavirin [Copegus]
DrugBank: Ribavirin elaidate (DB17193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000-1600 mg day orally for 48 weeks.
Trial: NCT00545233
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
Trial: NCT00591253
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
Trial: NCT00591253
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
Trial: NCT00691145
Drug: tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal
Trial: NCT00481247
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, oral, dasatinib 50-140 mg once daily (QD)
Trial: NCT00046514
Drug: ABI-007
RxNorm normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01880216
Drug: Bemiparin sodium
RxNorm normalized name: bemiparin sodium
DrugBank: Bemiparin (DB09258)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous application daily for 7±2 days
Trial: NCT01880216
Drug: Enoxaparin sodium
RxNorm normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous for 7±2 days
Trial: NCT04068610
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV infusion of durvalumab as stated in arm description.
Trial: NCT04068610
Drug: Oleclumab
RxNorm normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of oleclumab as stated in arm description.
Trial: NCT04068610
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV infusion of bevacizumab as stated in arm description.
Trial: NCT03827837
Drug: Famitinib
RxNorm normalized name: Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a small-molecule multikinase inhibitor
Trial: NCT00481247
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets, oral, imatinib 200-800 mg, QD
Trial: NCT01163266
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encapsulated vortioxetine immediate release tablets
Trial: NCT03874806
Drug: Ropivacaine 0.25%-NaCl 0.9% Injectable Solution
RxNorm normalized name: ROPivacaine 0.25%-NaCl 0.9% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% ropivacaine administered through a nerve catheter
Trial: NCT03874806
Drug: Ropivacaine 0.2%-NaCl 0.9% Injectable Solution
RxNorm normalized name: ROPivacaine 0.2%-NaCl 0.9% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine administered through a nerve catheter
Trial: NCT00762983
Drug: loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to \< 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified.
Trial: NCT04821882
Drug: Dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose: 2 mL of 50% dextrose in 10 mL normal saline and injected by 11 sub urothelial injections
Trial: NCT02752204
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
Trial: NCT01712230
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months
Trial: NCT00647166
Drug: corticosteroid and placebo
RxNorm normalized name: abiraterone and corticosteroids
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Corticosteroid 1 mg/kg/day with a conventional decrease dose~* Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route
Trial: NCT03295058
Drug: GVHD Prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA 3 mg/kg) start day +5
Trial: NCT04399837
Drug: Spesolimab
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT01785186
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin 10 to 35 mg/kg
Trial: NCT01785186
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400mg
Trial: NCT01785186
Drug: isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: isoniazid 75 mg
Trial: NCT01785186
Drug: pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pyrazinamide 400 mg
Trial: NCT01785186
Drug: ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ethambutol 275 mg
Trial: NCT02182258
Drug: BIBF 1120 soft gelatine capsule
RxNorm normalized name: ritonavir
DrugBank: Gelatin (DB11242)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04192617
Drug: SM03
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SM03: 600 mg intravenous (IV)
Trial: NCT02912988
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
Trial: NCT01479504
Drug: nedaplatin and docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy
Trial: NCT01479504
Drug: cisplatin and docetaxel
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy
Trial: NCT04246190
Drug: CKD-501 and D759
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference drug, CKD-501 1T and D759 1T, QD, PO
Trial: NCT04246190
Drug: CKD-396
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug, CKD-396 1T, QD, PO
Trial: NCT04525157
Drug: Afamelanotide
RxNorm normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01457131
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2, IV(in the vein)on day 5 of each 25 day cycle
Trial: NCT03892148
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protocol for the use of diuretics
Trial: NCT03892148
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protocol for the use of diuretics
Trial: NCT03574246
Drug: chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: chlorhexidine gluconate + benzydamine hydrochloride oral rinse
Trial: NCT00798083
Drug: topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
Trial: NCT03242382
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
Trial: NCT01424774
Drug: CardioGen-82
RxNorm normalized name: CardioGen-82
DrugBank: Rubidium Rb-82 (DB09479)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
Trial: NCT02931565
Drug: Olinciguat
RxNorm normalized name: Olinciguat
DrugBank: Olinciguat (DB15238)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT00078468
Drug: PELITREXOL/AG-2037
DrugBank: Pelitrexol (DB12757)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00503126
Drug: bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: anticoagulation
Trial: NCT06462001
Drug: Mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMC is administered intravesically as per usual standard of care
Trial: NCT00609895
Drug: INSULIN GLARGINE
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00168337
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
Trial: NCT02151461
Drug: Low Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1100 mg L Leucine in combination with 125 mg of Metformin BID
Trial: NCT02151461
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
Trial: NCT02151461
Drug: Mid Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1100 mg of Leucine in combination with 250 mg Metformin BID
Trial: NCT02151461
Drug: High Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1100 mg of Leucine in combination with 500 mg Metformin BID
Trial: NCT04988945
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500mg Durvalumab administered IV over 60 minutes on Day 1 of each immunotherapy treatment every 4 weeks until disease progression (PD)
Trial: NCT04988945
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg Tremelimumab administered over 60 minutes on Day 1 of cycle 1.
Trial: NCT01324245
Drug: Fenoldopam
RxNorm normalized name: Fenoldopam
DrugBank: Fenoldopam (DB00800)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous infusion at 0.5 mics/Kg/min for three hours
Trial: NCT00231049
Drug: AG-707
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03406689
Drug: Artificial tear
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop Artificial Tears will be instilled 45' prior to the IVI.
Trial: NCT00520351
Drug: ClearCare
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: contact lens care system
Trial: NCT00520351
Drug: Optifree Replenish
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: contact lens care system
Trial: NCT00001728
Drug: Fosamax (Alendronate)
RxNorm normalized name: alendronate Oral Tablet [Fosamax]
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00646152
Drug: Poly-ICLC
RxNorm normalized name: Poly-ICLC
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01927341
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
Trial: NCT02801448
Drug: sulforaphane
RxNorm normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulforaphane-containing broccoli sprout extracts
Trial: NCT03654066
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botox injection in the LES
Trial: NCT00413764
Drug: tibolone
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibolone (2.5 mg) over 24 weeks